{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-010644","form_type":"8-K","ticker":"CCCC","cik":"0001662579","company_name":"C4 Therapeutics, Inc.","filed_at":"2022-03-16T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.686694+00:00","generated_at":"2026-06-26T22:23:37.432019+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"C4 Therapeutics appoints Utpal Koppikar to board; Elena Prokupets resigns","bullets":["Utpal Koppikar elected as director effective March 16, 2022; will chair Audit Committee and serve on Organization, Leadership and Compensation Committee.","Koppikar is CFO of Atara Biotherapeutics; previously VP at Gilead Sciences and executive director at Amgen.","Granted stock options for 41,200 shares vesting over three years with annual cliff.","Elena Prokupets resigned March 10, 2022; resignation not due to any disagreement with the company."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-010644","json":"https://secwatch.observer/filing/0001564590-22-010644.json","markdown":"https://secwatch.observer/filing/0001564590-22-010644.md","text":"https://secwatch.observer/filing/0001564590-22-010644.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662579/000156459022010644/0001564590-22-010644-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662579/000156459022010644/cccc-8k_20220310.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T22:23:37.432019+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2e96383fc5","claim":"Elena Prokupets resigned as Director at C4 Therapeutics, Inc..","evidence_excerpt":"Elena Prokupets, Ph.D., resigned as a director and as a member of the Audit, Compensation and Nominating and Corporate Governance Committees of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1662579/000156459022010644/0001564590-22-010644-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"5bdb7f9db5","claim":"Utpal Koppikar was elected as Director at C4 Therapeutics, Inc..","evidence_excerpt":"elected Utpal Koppikar as a director effective immediately and as chair of the Audit Committee","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1662579/000156459022010644/0001564590-22-010644-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}